North Central London
Joint Formulary
 
back
8 Malignant disease and immunosuppression

The formulary for systemic anti-cancer treatments should be viewed alongside the 'National Cancer Drugs Fund list'

https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/

08-01-05 Taxanes

Cabazitaxel
Restricted

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary to WH
Link  NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
 

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF  HCD
Docetaxel
Restricted

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • RFL:
    • No restrictions stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Breast and lung cancer
Link  NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Link  NICE TA109: Breast cancer (early) - docetaxel
 

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF
Paclitaxel
Restricted

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below 
  • RFL:
    • No restrictions stated
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
Link  NICE TA108 (not recommended): Paclitaxel for the adjuvant treatment of early node-positive breast cancer
Link  NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Link  NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
 

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF
Paclitaxel - Albumin Bound Formulation Abraxane®
Restricted

Approved for:

  • Adjuvant or neoadjuvant therapy and metastatic disease breast cancer for those with hypersensitivity to taxanes. Hypersensitivity is defined as grade 3 hypersensitivity (August 2013).
  • See NICE TA for use of Abraxane for other cancers

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • Restricted to breast and pancreatic cancer patients as per NHS England criteria and NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
Link  NICE TA362 (not recommended): Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal)
Link  NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
 

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF  HCD